Patent assignee · FR · COMPANY

THERAVECTYS

🏢 View company profile →
9Patents
9Active
9Granted
44Portfolio score

Filing activity: Aug 1, 2008 → Jul 20, 2017 · 1 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US8420104B2 Lentiviral gene transfer vectors and their medicinal applications Emerging Cross-Sectional Technologies 8 Active
US10752668B2 Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule Chemistry; Metallurgy 4 Active
US9657311B2 Lentiviral vectors containing an MHC class I, MHC class II, or B2 microglobulin upstream promoter sequence Chemistry; Metallurgy 3 Active
US8709799B2 Lentiviral gene transfer vectors and their medicinal applications Emerging Cross-Sectional Technologies 1 Active
US9328146B2 Lentiviral gene transfer vectors and their medicinal applications Emerging Cross-Sectional Technologies 1 Active
US9987351B2 Lentiviral vectors for generating immune responses against human T Lymphotrophic Virus Type 1 Chemistry; Metallurgy 0 Active
US8951535B2 Lentiviral vectors containing an MHC class I promoter Chemistry; Metallurgy 0 Active
US9752160B2 Use of non-subtype B gag proteins for lentiviral packaging Chemistry; Metallurgy 0 Active
US10864265B2 Lentiviral vectors for expression of hepatitis B virus (HBV) antigens Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.